GSK’s two-drug HIV treatment clears key clinical assessments

Date: 2018-07-26   Author: Shikha Sinha  Category: #news

GSK’s two-drug HIV treatment clears key clinical assessments

GlaxoSmithKline, a British pharmaceutical company, has announced through clinical study results that their two-drug HIV treatment works just as well as the conventional triple therapy, even for individuals with comparatively high levels of the virus causing AIDS.

Investors and doctors alike had been anxious to see how 3TC, also known as the experimental combination of lamivudine and dolutegravir, measures up to highly potent triple drugs marketed by GSK’s rival Gilead Sciences.

As per reliable sources, ViiV Healthcare unit has developed the latest treatment. The company, in which GSK has a majority stake, had announced successful results from the two supposed GEMINI studies in the previous month.  However, the details of the study were not divulged until the International AIDS Conference was held in Amsterdam, wherein the unveiling took place.

An expert HIV researcher from Argentina, Pedro Cahn who piloted the GEMINI studies stated that the outcome showed the two-drug treatment to be as effective as the three-drug therapy. After monitoring 1400 patients over a span of 48 weeks, researchers discovered that 91% of the individuals taking lamivudine and dolutegravir showed high levels of viral control when compared with 93% of the individuals on the three-drug course – a negligible statistical gap.

Inability in controlling HIV, or virologic failure rates were steady and did not cross the 1% mark across all groups with none of the patients developing drug resistance, cite sources.

Cahn stated that this is a new treatment option and that the primary motivation of developing this course of treatment was to minimize the burden of the quantity of drugs patients had to ingest when on a life-long treatment plan.

GSK is anticipating that the shift toward two-drug course rather than the three-drug regimen will catapult its sales as it is offering treatment with fewer toxic side-effects. The company also points out that the two-drug course would be more affordable as lamivudine is out of patent restrictions.



About Author


Shikha Sinha linkdin-boxtwitter

Shikha Sinha

Shikha currently manages the content team at AlgosOnline. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market research, and business development domains. Her other interests inc...

Read More

Post Recommendents

Probiotics Dietary Supplement Market Research Report Analysis, Industry Size and Growth 2028

Author: Ashwin Naphade

Probiotics Dietary Supplement Market report provides key statistics on the market status of the Probiotics Dietary Supplement Industry and is a valuable source of guidance and direction for companies and individuals interested in the Probiotics D...


Qualitative analysis of Artificial Lens Market Revenue & Industry Analysis By 2028

Author: Ashwin Naphade

Artificial Lens market offers vital data regarding the geographical reach, competitive outlook, COVID-19 impact, alongside crucial insights to market segmentations and their relevant contribution.

.

Request a sample Report of ...


Blood Vessel Prosthesis market to showcase an annual healthy growth rate over 2022-2028

Author: Ashwin Naphade

Market Study Report has announced the launch of Blood Vessel Prosthesis market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive o...